Affordable Access

deepdyve-link
Publisher Website

Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports

Authors
  • Guo, Jun-Hui
  • Wang, Yuan-Yuan
  • Zhang, Jiang-Wei
  • Liu, Pei-Min
  • Hao, Yan-Jun
  • Duan, Hai-Rui
Type
Published Article
Journal
World Journal of Clinical Cases
Publisher
Baishideng Publishing Group Inc
Publication Date
Apr 06, 2020
Volume
8
Issue
7
Pages
1326–1336
Identifiers
DOI: 10.12998/wjcc.v8.i7.1326
PMID: 32337210
PMCID: PMC7176611
Source
PubMed Central
Keywords
Disciplines
  • Case Report
License
Unknown

Abstract

BACKGROUND Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor. Apatinib has demonstrated encouraging antitumor activities. This study aimed to observe the efficacy and safety of apatinib for the treatment of multiple brain micrometastases. CASE SUMMARY We report two patients with multiple brain micrometastases after failure of second-line treatment. Both patients had extracerebral metastases. When the patients took 250 mg/d apatinib orally, the intracerebral lesions disappeared. The extracerebral lesions were partially alleviated. Both patients had a progression-free survival of more than 12 mo and were still stable. The safety was good. The main adverse events (AEs) were mild hypertension and proteinuria, which could be controlled. CONCLUSION Apatinib has clear efficacy and good tolerance in patients with multiple brain micrometastases after failure of second-line treatment.

Report this publication

Statistics

Seen <100 times